Enanta Pharmaceuticals (NASDAQ: ENTA)
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-04 | ||||||
REV |
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.430 | -1.630 | -0.2000 | ||||
REV | 20.670M | 18.716M | -1.954M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Enanta Pharmaceuticals (NASDAQ: ENTA) through any online brokerage.
Other companies in Enanta Pharmaceuticals’s space includes: Avidity Biosciences (NASDAQ:RNA), Syndax Pharmaceuticals (NASDAQ:SNDX), Replimune Group (NASDAQ:REPL), Arcutis Biotherapeutics (NASDAQ:ARQT) and FibroGen (NASDAQ:FGEN).
The latest price target for Enanta Pharmaceuticals (NASDAQ: ENTA) was reported by Evercore ISI Group on Wednesday, June 1, 2022. The analyst firm set a price target for 39.00 expecting ENTA to fall to within 12 months (a possible -13.35% downside). 25 analyst firms have reported ratings in the last year.
The stock price for Enanta Pharmaceuticals (NASDAQ: ENTA) is $45.01 last updated June 24, 2022, 8:00 PM UTC.
There are no upcoming dividends for Enanta Pharmaceuticals.
Enanta Pharmaceuticals’s Q3 earnings are confirmed for Thursday, August 4, 2022.
There is no upcoming split for Enanta Pharmaceuticals.
Enanta Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.